Relapse vaccine is a promising treatment for patients with AML
The allogeneic leukemia-derived dendritic cell vaccine – DCP-001 – has shown safety, humoral, and cellular immune responses in the treatment of acute myeloid leukemia. In this MEDtalk Bjorn T. Gjertsen, MD, PhD, Professor of Hematology at the University of Bergen, Norway, presents the effects of the vaccine regarding prognostic factor and relapse of disease. The results are very promising as the vaccine induce deeper responses and support better survival in patients with AML.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.